Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal Metastases (GlobeNewswire) - Apr 18, 2023 - "Plus Therapeutics, Inc...announced the completion of Cohort 3 of the ReSPECT-LM Phase 1/2a dose-escalation clinical trial of rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors less than one month since its initiation, demonstrating rapid enrollment. Additionally, the Company has expanded the number of clinical trial sites to include Northwestern Memorial Hospital in Chicago, marking the first expansion of the ReSPECT-LM trial beyond Texas....We are preparing to reconvene with the U.S. Food and Drug Administration (FDA) to provide data from Cohorts 1 through 3 and determine next steps for Part B of the Phase 1 trial....The Company anticipates presenting the entire Phase 1/Part A data at medical meetings in the second half of 2023."
FDA event • P1 data • Trial status • Brain Cancer • CNS Tumor • Oncology • Solid Tumor
|